Skip to main content

Table 2 Best overall response to treatment in the SOX+B-mab and SOX+C-mab population

From: Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study)

Outcomes (RECIST v1.1) SOX+B-mab
(n = 22)
SOX+C-mab
(n = 23)
Total
(n = 45)
Overall response rate (CR + PR) 13 (59.1%) 10 (43.5%) 23 (51.1%), P = 0.29
Disease control rate (CR + PR + SD) 20 (90.9%) 21 (91.3%) 41 (91.1%), P = 0.96
 Complete response (CR) 0 (0.0%) 0 (0.0%) 0 (0.0%)
 Partial response (PR) 13 (59.1%) 10 (43.5%) 23 (51.1%)
 Stable disease (SD) 7 (31.8%) 11 (47.8%) 18 (40.0%)
 Progressive disease (PD) 1 (4.5%) 1 (4.3%) 2 (4.4%)
 Could not be evaluated (NE) 1 (4.5%) 1 (4.3%) 2 (4.4%)
Conversion surgery 4 (18.2%) 3 (13.0%) 7 (15.6%)
 R0 resection 4 (18.2%) 1 (4.3%) 5 (11.1%), P = 0.19
 R2 resection 0 2 (8.7%) 2 (4.4%)